Alentis is the leading biotech company developing anti-Claudin-1 therapies. Claudin-1 is an extraordinary target that plays a key role in many solid tumors and fibrosis. We are committed to unlocking the broad potential of Claudin-1 and bringing much-needed new medicines to patients.